Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

Vaxcell-Bio Therapeutics Revenue

In the year 2024, Vaxcell-Bio Therapeutics had annual revenue of 1.90B KRW with 13,737.28% growth. Vaxcell-Bio Therapeutics had revenue of 921.53M in the quarter ending December 31, 2024, with 6,615.06% growth.

• Revenue: 1.90B
• Revenue Growth: +13,737.28%
• P/S Ratio: n/a
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 112.22B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	1.90B	1.89B	13,737.28%
Dec 31, 2023	13.72M	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	-	-	-
Dec 31, 2020	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2024

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 6, 2026

Data Sources Report a data error